26
Participants
Start Date
October 31, 2008
Primary Completion Date
July 31, 2013
Study Completion Date
July 31, 2013
CG100649 (2 mg)
CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
Celecoxib
Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
Placebo capsules
Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
Naproxen
Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
Acetazolamide
Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)
CG100649 (8 mg)
CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine, Philadelphia
Collaborators (1)
CrystalGenomics, Inc.
INDUSTRY
University of Pennsylvania
OTHER